We grouped patients carrying genetic abnormalities associated with BCR‐ABL1‐like ALL including ABL‐class fusions, CRLF2 rearrangements, JAK‐STAT pathway mutations and RAS pathway mutations, and classified them as BCR‐ABL1‐like ALL (n = 25, 13.2% of B‐ALL) (Table 2). This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.